Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Novozymes In Recombumin Supply Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

Novozymes In Recombumin Supply Pact

To be used for the development of a new GLP-1 analog in Phase II trials for Type 2 diabetes

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Novozymes Biopharma has concluded an exclusive supply agreement with ConjuChem LLC of Los Angeles, CA. Novozymes will supply its recombinant human albumin, Recombumin, for use in the development of a new GLP-1 analog in Phase II trials for Type 2 diabetes. The use of Recombumin has the potential to significantly reduce dosing frequency, allowing patients to self-inject once per week instead of once or twice daily.

“This supply agreement is a great example of using Novozymes’ Recombumin as a vehicle for extending the half-life of peptides in drug delivery applications,” said Thomas Videbæk, executive vice president of Novozymes’ BioBusiness. “Also the agreement for this new drug will potentially pave the way for the use of Recombumin in other peptide-based therapies.”

Patrick Soon-Shiong, M.D., chief executive officer at ConjuChem, said, “This exclusive agreement is an excellent partnership for Conjuchem. The Recombumin technology, and the strong commitment from Novozymes, will be key as we develop next generation treatment for a disease affecting more than 360 million people worldwide.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics